Alejandro Navarro

5.7k citations

110 papers · 2.6k indexed · 2 hit papers · h-index 19

Impact in

Oncology top 1%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Peptidase Inhibition and Analysis
Pulmonary and Respiratory Medicine top 2%
- Lung Cancer Treatments and Mutations
- Occupational and environmental lung diseases

Papers in ⓘ

Oncology 82
- Lung Cancer Research Studies 61
- Peptidase Inhibition and Analysis 21
- Cancer Immunotherapy and Biomarkers 14
- Pancreatic and Hepatic Oncology Research 10
Pulmonary and Respiratory Medicine 49
- Lung Cancer Treatments and Mutations 33

Co-authors: Enriqueta Felip (43 shared papers)S. Cedrés (33 shared papers)Alex Martínez‐Martí (24 shared papers)Pablo Martínez (8 shared papers)Melissa L. Johnson (4 shared papers)Alice T. Shaw (3 shared papers)Antonello Abbattista (3 shared papers)Todd M. Bauer (3 shared papers)
Journals: Journal of Clinical Oncology (33 papers)Annals of Oncology (21 papers)Journal of Thoracic Oncology (17 papers)Lung Cancer (5 papers)Clinical & Translational Oncology (3 papers)
Partner nations: Spain United States France

In The Last Decade

Alejandro Navarro

104 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study 2020 · 491 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 Journal of Clinical Oncology
2017 The Lancet Oncology

Peers

Countries citing papers authored by Alejandro Navarro

Since Specialization

Citations

This map shows the geographic impact of Alejandro Navarro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alejandro Navarro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alejandro Navarro more than expected).

Fields of papers citing papers by Alejandro Navarro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alejandro Navarro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alejandro Navarro. The network helps show where Alejandro Navarro may publish in the future.

Co-authors

The 25 scholars most cited alongside Alejandro Navarro, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Alejandro Navarro Line = papers co-authored together Alejandro Navarro links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 110 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study Journal of Clinical Oncology ·Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodríguez‐Abreu, Mirjana Wollner, James Chih‐Hsin Yang, Julien Mazières, Francesco Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, Victoria Ebiana, M. Catherine Pietanza, Hye Ryun Kim, (unknown) Hit paper breakdown →	2020	491
2	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial The Lancet Oncology ·Alice T. Shaw, Enriqueta Felip, Todd M. Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel‐Vinay, Justin F. Gainor, Melissa L. Johnson, Jörg Dietrich, Leonard P. James, Jill S. Clancy, Joseph Chen, Jean‐François Martini, Antonello Abbattista, Benjamin Solomon Hit paper breakdown →	2017	487
3	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma Cancer Research ·Aleix Prat, Alejandro Navarro, Laia Paré, Noemı́ Reguart, Patricia Galván, Tomás Pascual, Alex Martínez‐Martí, Paolo Nucíforo, Laura Comerma, Llúcia Alós, Núria Pardo, S. Cedrés, Cheng Fan, Joel S. Parker, Lydia Gaba, Iván Victoria, Núria Viñolas, Ana Vivancos, Ana Arance, Enriqueta Felip	2017	277
4	Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer Clinical & Translational Oncology ·S. Cedrés, Davis Y. Torrejon, A. Martínez, Pablo Martínez, Alejandro Navarro, Esther Zamora, N. Mulet-Margalef, Enriqueta Felip	2012	224
5	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM) PLoS ONE ·S. Cedrés, Santiago Ponce-Aix, Jon Zugazagoitia, Irene Sansano, Ana B. Enguita, Alejandro Navarro, Alex Martínez‐Martí, Pablo Martínez, Enriqueta Felip	2015	146
6	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer Targeted Oncology ·Todd M. Bauer, Alice T. Shaw, Melissa L. Johnson, Alejandro Navarro, Justin F. Gainor, Holger Thurm, Yazdi K. Pithavala, Antonello Abbattista, Gerson Peltz, Enriqueta Felip	2020	79
7	Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study Annals of Oncology ·Taofeek K. Owonikoko, H.R. Kim, Ramaswamy Govindan, Neal Ready, Martin Reck, Solange Peters, Shaker R. Dakhil, Alejandro Navarro, Jerónimo Rafael Rodríguez‐Cid, Michael Schenker, J.S. Lee, Vanesa Gutiérrez, Ivor Percent, Daniel Morgensztern, Justin Fairchild, Christine Baudelet, K. Park	2019	66
8	DualMET andERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC) Annals of Oncology ·Alex Martínez‐Martí, Enriqueta Felip, Judit Matito, Elisabetta Mereu, Alejandro Navarro, S. Cedrés, Núria Pardo, A. Martinez de Castro, Jordi Remón, Josep M. Miquel, Amy Guillaumet-Adkins, Ernest Nadal, Gustavo Rodríguez-Esteban, Oriol Arqués, Roberta Fasani, Paolo Nucíforo, Holger Heyn, Alberto Villanueva, Héctor G. Pálmer, Ana Vivancos	2017	55
9	SKYSCRAPER-02: Primary results of a phase III, randomized, double-blind, placebo-controlled study of atezolizumab (atezo) + carboplatin + etoposide (CE) with or without tiragolumab (tira) in patients (pts) with untreated extensive-stage small cell lung cancer (ES-SCLC). Journal of Clinical Oncology ·Charles M. Rudin, Stephen V. Liu, Shun Lü, Ross A. Soo, Min Hee Hong, Jong-Seok Lee, Maciej Bryl, Daphne W. Dumoulin, Achim Rittmeyer, Chao‐Hua Chiu, Özgür Özyılkan, Alejandro Navarro, Silvia Novello, Yuichi Ozawa, Raymond D. Meng, Tien Hoang, Anthony Lee, Xiaohui Wen, Meilin Huang, Martin Reck	2022	55
10	Overview of Checkpoint Inhibitors Mechanism of Action: Role of Immune-Related Adverse Events and Their Treatment on Progression of Underlying Cancer Frontiers in Medicine ·Patricia Iranzo, Ana Callejo, J.D. Assaf, Gaspar Molina, D. López-Valbuena, David García-Illescas, Núria Pardo, Alejandro Navarro, Alex Martínez‐Martí, S. Cedrés, Caterina Carbonell, Joan Frigola, Ramon Amat, Enriqueta Felip	2022	53
11	Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM) Lung Cancer ·S. Cedrés, Santiago Ponce-Aix, Nuria Pardo-Aranda, Alejandro Navarro, Alex Martínez‐Martí, Jon Zugazagoitia, Irene Sansano, M.A. Montoro, Ana B. Enguita, Enriqueta Felip	2016	31
12	Rogaratinib in patients with advanced urothelial carcinomas prescreened for tumor FGFR mRNA expression and effects of mutations in the FGFR signaling pathway. Journal of Clinical Oncology ·Markus Joerger, Philippe A. Cassier, Nicolas Penel, Richard Cathomas, Heike Richly, Martin Schostak, Andreas Janitzky, Martin Wermke, Lucia Nogová, David Tai, Cyrus Sayehli, Carsten Grüllich, Enrique Grande, Alejandro Navarro, Se Hoon Park, Hendrik Nogai, Sebastian Bender, Peter Ellinghaus, Martin Schüler	2018	29
13	Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (MET^Amp/Ex14∆). Journal of Clinical Oncology ·D. Ross Camidge, Filip Jankú, Alejandro Martínez‐Bueno, Daniel V.T. Catenacci, Jeeyun Lee, Se‐Hoon Lee, Afshin Dowlati, Kristoffer Staal Rohrberg, Alejandro Navarro, Yong Wha Moon, Mark M. Awad, Rebecca S. Heist, Thomas Poulsen, Arielle Yablonovitch, Lindsay Fosler, Helle Rudbaek, Frank Nygaard, Debra L. Wood, Rita P. Dalal, Enriqueta Felip	2020	28
14	A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer Clinical Lung Cancer ·Lauren A. Byers, Alejandro Navarro, Eric Schaefer, Melissa L. Johnson, Mustafa Özgüroğlu, Ji‐Youn Han, Igor Bondarenko, İrfan Çiçin, Konstantin H. Dragnev, Adam Abel, Xuejing Wang, Samuel McNeely, Scott M. Hynes, Aimee Bence Lin, Martin Förster	2021	27
15	Molecular profiling of long‐term responders to immune checkpoint inhibitors in advanced non‐small cell lung cancer Molecular Oncology ·Joan Frigola, Alejandro Navarro, Caterina Carbonell, Ana Callejo, Patricia Iranzo, S. Cedrés, Alex Martínez‐Martí, Núria Pardo, (unknown), Eduardo Martínez de Dueñas, José Jiménez, Irene Sansano, Francesco M. Mancuso, Paolo Nucíforo, Luis M. Montuenga, Montse Sánchez‐Céspedes, Aleix Prat, Ana Vivancos, Enriqueta Felip, Ramon Amat	2020	27
16	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches Lung Cancer ·Jordi Remón, Núria Pardo, Alex Martínez‐Martí, S. Cedrés, Alejandro Navarro, Ana Castro, Enriqueta Felip	2017	25
17	ADRIATIC: Durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC). Journal of Clinical Oncology ·David R. Spigel, Ying Cheng, Byoung Chul Cho, К. К. Лактионов, Jian Fang, Yuanbin Chen, Yoshitaka Zenke, Ki Hyeong Lee, Qiming Wang, Alejandro Navarro, Reyes Bernabé, E.L. Buchmeier, John W. C. Chang, Isamu Okamoto, Sema Sezgin Göksu, A. Badzio, Bethany Gill, Hema Gowda, Haiyi Jiang, Suresh Senan	2024	25
18	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer ESMO Open ·Juan Miguel Cejalvo, Wolfgang Jacob, Tania Fleitas, Enriqueta Felip, Alejandro Navarro, Maria Martinez‐García, Álvaro Taus Garcia, Natasha B. Leighl, Ulrik Lassen, Morten Mau‐Sørensen, Céline Adessi, Francesca Michielin, Ian James, Maurizio Ceppi, Max Hasmann, Maja Weisser, Andrés Cervantes	2019	22
19	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate? Lung Cancer ·Pablo Martínez, Alex Martínez‐Martí, Alejandro Navarro, S. Cedrés, Enriqueta Felip	2014	18
20	KEYNOTE-604: Pembrolizumab (pembro) or placebo plus etoposide and platinum (EP) as first-line therapy for extensive-stage (ES) small-cell lung cancer (SCLC). Journal of Clinical Oncology ·Charles M. Rudin, Mark M. Awad, Alejandro Navarro, Maya Gottfried, Solange Peters, Tibor Csőszi, Parneet Cheema, Delvys Rodríguez‐Abreu, Mira Wollner, Grzegorz Czyżewicz, James Chih‐Hsin Yang, Julien Mazières, Francesco Orlandi, Alexander Luft, Mahmut Gümüş, Terufumi Kato, Gregory P. Kalemkerian, Yiwen Luo, M. Catherine Pietanza, Hye Ryun Kim	2020	17

About Alejandro Navarro

Alejandro Navarro is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Epidemiology, having authored 110 papers that have together received 2.6k indexed citations. Recurring topics across this work include Lung Cancer Research Studies (61 papers), Lung Cancer Treatments and Mutations (33 papers), Cancer therapeutics and mechanisms (28 papers), Peptidase Inhibition and Analysis (21 papers), Neuroendocrine Tumor Research Advances (16 papers), Cancer Immunotherapy and Biomarkers (14 papers), Cancer Genomics and Diagnostics (10 papers) and Pancreatic and Hepatic Oncology Research (10 papers). The work is most often cited by research in Oncology (2.0k citations), Pulmonary and Respiratory Medicine (1.3k citations), Cancer Research (305 citations), Epidemiology (613 citations) and Immunology (304 citations). Alejandro Navarro has collaborated with scholars based in Spain, United States and France. Frequent co-authors include Enriqueta Felip, S. Cedrés, Alex Martínez‐Martí, Pablo Martínez, Melissa L. Johnson, Alice T. Shaw, Antonello Abbattista, Todd M. Bauer, Justin F. Gainor and Benjamin Besse. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Lung Cancer and Clinical & Translational Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact